News
Dr. Newton Achieves First Activation and First Patient Screened in Hypertension Trial
CHARLESTON, SC – DelRicht Research is proud to recognize Dr. E. Marshall Newton and the Charleston research team for achieving early, study-defining milestones in a Phase 2b clinical trial evaluating a novel treatment for hypertension. Through focused coordination and operational preparedness, the site achieved first site activated and first patient...
Dr. Ira Thorla Contributes to Phase 2 Study Evaluating Combination Therapy for Vitiligo
Vitiligo is a chronic autoimmune condition that causes loss of pigmentation and affects millions worldwide, often impacting confidence, quality of life, and emotional well-being. As research into new treatment combinations accelerates, a recently published Phase 2 study offers encouraging insight into how ruxolitinib 1.5% cream and narrow-band UVB phototherapy (NB-UVB)...
Dr. Campion Achieves First Patient Screened & Enrolled in Phase III SAD Trial
NEW ORLEANS, LA – We are proud to recognize Dr. Caroline Campion and the exceptional research team in New Orleans for achieving a remarkable series of milestones in a Phase 3 clinical trial for Social Anxiety Disorder (SAD). Through seamless coordination, strong patient engagement, and precise operational execution, the site...
150% of Enrollment Goal Achieved Across Four Sites in a Phase 3 Migraine Trial
DelRicht Research is proud to highlight the outstanding performance of our site teams across Atlanta, Gulfport, New Orleans, and Tulsa in a recent Phase 3 clinical trial for migraine. Designed to evaluate the safety and efficacy of an investigational therapy in adults ages 18-70, the study enrolled 400 participants across...
Dr. Patrick Dennis Recognized as Top Enroller in a Phase 2 Hypertension Trial
DelRicht Research is proud to highlight the outstanding performance of Dr. Patrick Dennis and the New Orleans site team at Touro Medical Center in a recent Phase 2 clinical trial evaluating an investigational therapy for adults with uncontrolled hypertension. The study, designed to assess safety and efficacy across 40 U.S....
First to Activate, First to Randomize, and 247% of Goal Achieved in a Phase 2 HS Trial
DelRicht Research is proud to highlight the outstanding performance of our dermatology teams in a recent Phase 2 clinical trial for hidradenitis suppurativa (HS), a chronic and often painful inflammatory skin condition that impacts quality of life for patients worldwide. Across our participating sites in Baton Rouge, LA, and Atlanta,...
Proven Results in Vitiligo Trials: DelRicht Research Delivers Scale, Speed, and Expertise
As dermatology research advances in both innovation and patient demand, DelRicht Research continues to stand out as a trusted partner for sponsors and CROs conducting vitiligo and other pigmentary disorder trials. With 9 vitiligo studies completed in the past five years, and 4 sites ranked as top enrollers across multicenter...
Leading in Gout Research: 39.6% of Participants and 7 of the Top 10 Enrollers in a Phase 3 Trial
DelRicht Research is proud to showcase the outstanding performance of our investigators and site teams in a pivotal US-based Phase 3 trial evaluating treatment for gout, a form of inflammatory arthritis that affects more than 9 million adults in the U.S. Over the course of an 8-month enrollment period, our...
Achieving 310% of Expected Enrollment Goal in a Phase 2/3 AGA Trial
DelRicht Research is proud to spotlight the exceptional performance of our investigators and site teams in a U.S.-based Phase 2/3 clinical trial evaluating treatment for androgenetic alopecia (AGA), a condition that affects millions of males and females and is characterized by progressive loss of terminal hair of the scalp. Over...
FDA Approves Opzelura® for Children Ages 2–11 with Atopic Dermatitis
The U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor developed by Incyte, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well...
